HyperLab Blog

"HyperLab 2.0," equipped with more advanced features and workflows, has been released.

The HyperLab AI assistant is an LLM-based tool specialized for drug development, automating tasks from literature review to data analysis to maximize research productivity.

The $500B “Stargate Project” — What’s behind President Trump’s bold move, and what does it really mean?

Introduces the concept of deep learning architecture and compares two representative models: Transformer and Titans.

Here’s why AI drug development is gaining attention, along with its past, present, and future at a glance

Hyper Screening X utilizes RxnFlow to efficiently explore a 7-trillion-compound ultra-large library, identifying innovative drug candidates with low binding energy and over 60% synthetic feasibility.

In this article, we introduce the development background and outstanding performance of PIGNet, which overcomes the limitations of traditional molecular docking by integrating deep learning with physical laws.

Introducing the AI-driven drug discovery research unveiled at ICLR 2025: RxnFlow, DynamicFlow, and NEXT-MOL

DeepSeek AI has recently emerged as a major player in the AI industry, offering cutting-edge models with high performance at a significantly lower cost.

In January 2025, the U.S. Food and Drug Administration (FDA) approved several new drugs targeting various diseases.